Table 1 Detailed clinical characteristics of all participants

Sample Sizes

11

22

-

Female

4(36.36%)

7(31.82%)

0.546

Age-years

49.55 ± 3.904

44.45 ± 2.770

0.2964

Duration of disease-years

-

3.50 ± 0.63

-

With thymoma

-

-

-

Anti-AChR antibody (+)

-

22(100%)

-

Immunosuppressive treatment

-

-

-

Inflammatory disease history

(with the last months)

-

-

-

Antibiotic treatment

(within the last 3 months)

-

-

-

MGFA classification

IIa

-

2

-

IIb

-

20

-